Market news
Detailed price information for Protalix Biotherapeutics (PLX-A) from The Globe and Mail including charting and trades.
Rezolute (NASDAQ:RZLT) said the FDA is continuing its review of additional Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism after the study failed to meet its primary endpoint, leaving the potential regulatory path unresolved and without a specific timeline for agency feedback. Key Investor TakeawaysThe FDA review remains ongoing as the agency evaluates whether there is a potential regulatory path forward for ersodetug in congenital hyperinsulinism.
Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.
REDWOOD CITY, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 28-29, 2026. Management will be participating in one-on-one investor meetings throughout the conference. Investors in
This is the newest page. Registered accounts read further back.